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SCIENCE @LERT
Landscaper seeks remunerative position
Woodford-Richens K, Williamson J, Bevan S, et al.
Allelic loss at SMAD4 in polyps from juvenile polyposis
patients and use of fluorescence in situ hybridization to
demonstrate clonal origin of the epithelium. Cancer Res
2000;60:2477–82.
Abstract
Juvenile polyposis syndrome (JPS) is an inherited genetic
defect resulting in production of multiple hamartomas,
some of which subsequently develop into carcinomas.
About 30% of these patients are known to have a hetero-
zygotic defect in the SMAD4 gene that codes for a
mediator of transforming growth factor beta signalling.
The loss of one of the two normal SMAD4 alleles is not
thought to be suYcient to induce hamartomas but
requires the additional loss of the residual normal allele as
a secondary event. In patients with JPS, the hamartomas
were thought to result from loss of the second normal
allele in stem cells that produced stromal cells and equally
importantly, that the overlying epithelium continued to
have one copy of the normal allele. On this basis, the sub-
sequent development of carcinoma of the epithelium was
considered to be due to the epithelial cells being
positioned in a highly abnormal microenvironment
(“soil”, hence landscaper theory). In this paper,
Woodford-Richens et al used fluorescence in situ hybridi-
sation (FISH) directed against the SMAD4 gene to probe
individual cells of the polyps to determine which had lost
both copies of SMAD4. They found that cells of the
stroma and epithelium, but not the inflammatory
infiltrate, had lost both alleles. A complicated theory
involving “cross talk” between a normal overlying epithe-
lium and an abnormal stroma does, therefore, not have to
be invoked to explain why the epithelial cells subse-
quently undergo malignant transformation. In addition,
the finding of identical secondary genetic defects in both
the epithelium and stroma of the hamartomas suggests
that they originate from the same stem cells and not from
distinct lineages as previously thought.
Comment
In 1998, Kinzlker and Vogelstein proposed a hypothesis
that expanded the limited data available from known spe-
cific genetic defects into a general mechanistic process
underlying malignant transformation of the gastro-
intestinal tract.1 In this model, classic tumour suppressor
genes such as APC function as “gatekeepers”, preventing,
in the case of APC, the translocation of â-catenin to the
nucleus where it complexes with Tcf- 4 and induces, inter
alia, expression of c-myc, with ensuing increased cell prolif-
eration and selection. Secondly, DNA repair proteins such
as MLH1 and MSH2 act as “caretakers” of the genome,
correcting mismatches in potentially important genes and
thus preventing their inappropriate expression. Finally, in a
series of diseases as disparate as inherited polyposis
syndromes such as juvenile polyposis syndrome (JPS), and
acquired conditions such as ulcerative colitis, changes in
the stromal component of the lesions—the clonal stromal
component of the hamartomas of JPS and the inflamma-
tory infiltrate in ulcerative colitis—result in an altered ter-
rain for epithelial cell growth which increases cancer
susceptibility (the “landscaper” hypothesis or eVect). In
this model, it is envisaged that mutations in the stroma of
the hamartomas in some way modulate epithelial cell pro-
liferation through epithelial:mesenchymal interactions or
epithelial damage (fig 1) while the cocktail of cytokines
secreted by the inflammatory infiltrate have similar eVects
on the colonic epithelium in ulcerative colitis. The detailed
molecular processes underlying this epithelial:mesenchy-
mal “cross talk” remain to be elucidated although several
examples have now been demonstrated. For example, large
Figure 1 Schematic representation of colonic mucosa, divided into stroma
and overlying epithelium.Regions with functionally relevant genetic defects
are shown in light and dark grey.Adenoca., adenocarcinoma. (A) Sporadic
colonic tumours acquire initial functional genetic defects in specific regions of
the epithelium, causing dysplastic polyps that may progress to carcinoma.
(B) In patients with conditions such as familial adenomatous polyposis, the
whole of the epithelium is aVected by a defect in a tumour suppressor gene,
resulting in the development of multiple dysplastic polyps. Some of these
polyps will subsequently progress to carcinoma.A defect in a tumour
suppressor gene resulting in multiple polyps can be considered a loss of control
of gatekeeper function. (C) Patients with juvenile polyposis syndrome (JPS)
initially develop hamartomas that were thought to have functional genetic
defects (that is, loss of the second functional allele of SMAD4) only aVecting
the stroma.The overlying epithelium was considered to be still under
functional genetic control of the remaining normal SMAD4 allele.According
to the landscaper hypothesis, this abnormality of the stroma subsequently
induced the overlying epithelium to progress to carcinoma.The recent paper
by Woodford-Richens et al casts doubt on the relevance of this model in
patients with JPS as they have identical genetic defects aVecting the
overlying epithelium.
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fold gastritis is a premalignant gastric condition that
involves Helicobacter pylori colonisation causing an increase
in cytokine (interleukin 1â) production by the inflamma-
tory infiltrate. This in turn stimulates hepatocyte growth
factor production and release by mesenchymal cells,
resulting in increased epithelial proliferation due to the
released hepatocyte growth factor binding to c-met
receptors on epithelial cells.2 In conditions such as these, a
general stimulation of proliferation may allow subpopula-
tions of cells with genetic defects to expand. Alternatively,
the constituents of the inflammatory cocktail, such as nitric
oxide, free radicals, and the cytokines themselves, may
result in direct genetic injury.3 4 In addition, modulation of
cytokine and growth factor production might influence cell
growth and cell:cell interactions via mechanisms such as
E-cadherin downregulation and â-catenin signalling.
While the jobs of the “caretaker” and “gatekeeper” appear
safe, at least for the moment, a recent paper by Woodford-
Richens and colleagues5 has made the position of the “land-
scaper” if not redundant at least tenuous. Epithelial
malignancies are increased in incidence in both JPS and
ulcerative colitis. The “landscaper” eVect was coined to
explain the apparent paradox of a stromal lesion—the
hamartomas of JPS—predisposing to an epithelial malig-
nancy: the abnormal stromal environment aVects the devel-
opment and growth of epithelial cells. JPS is one of several
hamartomatous polyposis syndromes which include Peutz-
Jeghers syndrome and Cowden’s syndrome, all of which
show multiple polyps in the gastrointestinal mucosa, with
cystically dilated glands and a cellular stroma composed of
smooth muscle, fibroblasts, and myofibroblasts. The spec-
trum of organ specific malignancies in these syndromes is
wide, with Peutz-Jeghers syndrome predisposing to breast,
cervix, and gastrointestinal cancers, Cowden’s syndrome to
thyroid and gastrointestinal tumours, and JPS to carcinomas
occurring in the intestine and stomach.
The molecular pathology of these lesions is now being
studied: in Peutz-Jeghers syndrome, the polyp epithelium
shows clonal allelic loss at the LKB1/STKII locus (encod-
ing a serine-threonine kinase) on chromosome 19p13.4,6
and carcinomas arising in Peutz-Jeghers syndrome show
loss of this wild-type allele, strongly favouring evolution
from hamartomas to carcinoma.7 8 Moreover, hamartomas,
and both adenomas and carcinomas in Cowden’s syn-
drome, show loss of heterozygosity at the PTEN/MMAC1
locus on chromosome 10q23.3,8 indicating that further
loss of the wild-type allele induces growth of the
hamartoma with occasional progression to carcinoma, in
the classical tumour suppressor gene mode.9
In JPS, germline mutations in the SMAD4, or DPC4
gene on chromosome 18q21.1, are seen in a proportion of
cases. Most SMAD4 mutations produce a truncated
protein that inactivates its function as a cytoplasmic
mediator in the transforming growth factor â signalling
pathway. SMAD4 appears to act as a classical tumour sup-
pressor (gene) in the colon10 11 and pancreas,12 and impor-
tantly, a high incidence of colorectal cancer has been
reported in a large JPS kindred, linked to 18q21.1, with
mutation in SMAD4, further suggesting that SMAD4 acts
as a tumour suppressor gene in JPS.13 14
Using microsatellites, Woodfood-Richens and colleagues5
have demonstrated that JPS polyps containing a constitu-
tional mutation often lose the wild-type SMAD4 allele,
strongly suggesting that somatic loss of this allele is the first
somatic mutation, inducing the growth of the hamartoma.
Thus hamartomas in JPS resemble colonic adenomas, rather
than primarily stromal lesions as previously thought.1 15 16
Moreover, FISH showed loss of SMAD4, not only in
epithelial cells but also in stromal fibroblasts and pericryptal
myofibroblasts, but not in lymphocytes.16
These findings indicate that the epithelium in JPS polyps
is clonal and somewhat surprisingly, this clonality is shared
by a component of the stroma, suggesting that the precur-
sors of these lesions are laid down very early in
development, before epithelial:mesenchymal diVerentia-
tion in the intestinal anlage, with later clonal expansion.
Alternatively, the mutation could occur later in life as a
stem cell with plasticity of a greater degree than is usually
considered.17 Certainly other neoplasms with multiple lin-
eages, such as hamartomas in tuberous sclerosis18 and
mixed mullerian tumours which contain both epithelial
and mesenchymal elements, appear clonal.19
This brings the epithelium into sharp focus in the
formation of the hamartoma and its progression to
carcinoma. Thus in JPS, and also possibly in other hamar-
tomatous lesions such as Peutz-Jeghers syndrome and
Cowden’s syndrome, the development of epithelial malig-
nancy is likely to be due to direct progression of the
epithelial component. Therefore, although the previous
suggestion of complex epithelial:mesenchymal interactions
remains a possibility in the causality of malignant develop-
ment of JPS, invocation of Occam’s razor dictates that the
most “straightforward” mechanism (involving the mini-
mum number of assumptions) should be considered to be
the most likely. There is no need therefore to incriminate
the “landscaper” hypothesis: in these lesions, job flexibility
or retraining to the “gatekeeper” career pathway seems
more appropriate. Whether or not openings are available
for landscapers in other terrains, such as the inflamed colon
of patients with ulcerative colitis, remains to be seen.
R J PLAYFORD
Department of Gastroenterology, Imperial College School of Medicine,
Hammersmith Hospital, Ducane Road,
London W12 ONN,UK
r.playford@ic.ac.uk
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LETTERS TO
THE EDITOR
Ulcerative colitis is more strongly linked
to chromosome 12 than Crohn’s disease
EDITOR,—Lesage and colleagues reported
failure to detect linkage to the IBD2 locus on
chromosome 12 in a panel of 95 families with
two or more relatives aVected by Crohn’s dis-
ease, and oVered some possible explanations
(Gut 2000;47:787–91). Linkage of inflamma-
tory bowel disease (IBD) to this region was
first detected in a panel of 160 families
containing multiple cases of Crohn’s disease,
ulcerative colitis, or both.1 Lesage et al justify
the study of Crohn’s disease families alone on
the grounds that “genetic heterogeneity in
susceptibility cannot be ruled out”, and they
imply that studying the Crohn’s disease sub-
group of IBD should thus maximise their
chance of successful replication. We concur
entirely that genetic heterogeneity is impor-
tant, and we have recently reported strong
evidence that it does indeed apply to
chromosome 12.2 However, our study of 367
multiply aVected families suggested a signifi-
cantly stronger contribution of this locus to
ulcerative colitis than Crohn’s disease.2 The
diVerence between the linkage results for
ulcerative colitis (LOD=3.91) and Crohn’s
disease (LOD=1.66) reached statistical sig-
nificance in two separate tests for heterogen-
eity. In the light of these results, the validity of
the exclusion map drawn by Lesage et al is
undermined. The exclusion map was based
on an assumed locus specific ës of 2.0, but
this value was derived from a panel contain-
ing Crohn’s disease, ulcerative colitis, and
mixed pairs.1 Given the evidence for a
substantially stronger contribution to ulcera-
tive colitis than Crohn’s disease, it is likely
that the true ës value for this locus with regard
to Crohn’s disease is much less than 2. Thus
the contention that Lesage et al can exclude a
contribution of IBD2 to Crohn’s disease sus-
ceptibility is probably not valid. As pointed
out in the accompanying editorial, simulation
studies have demonstrated that lod scores can
be expected to vary, particularly when the
study population is relatively small.3 Further-
more, the implication that a panel of 157
aVected relative pairs should provide suY-
cient power to detect linkage if this locus is
contributing to disease susceptibility is at
marked variance with the power calculations
derived by Suarez et al, Mandal et al, and
others.4 5
In many respects, the surprising feature is
that IBD2 has been replicated in as many as
five independent panels.3 The datasets that
have failed to detect linkage at this locus have
all contained predominantly or exclusively
Crohn’s disease pairs.6–8 Although IBD2
probably does contribute to Crohn’s disease
susceptibility, the eVect is likely to be weak
and thus would require very large panels of
multiply aVected families to have a realistic
expectation of replicating (or excluding) the
linkage result.
It is our view that attempts at fine mapping
IBD2 probably have the greatest chance of
success if they concentrate on panels of
families and individuals with ulcerative colitis,
which appears to be significantly more strongly
linked to this locus than Crohn’s disease.
M PARKES
J SATSANGI
D P JEWELL
Gastroenterology Unit,
RadcliVe Infirmary, Oxford, UK
D E WEEKS
M M BARMADA
Department of Human Genetics,
Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, PA,USA
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Department of Medicine and Center for Genomic
Sciences, University of Pittsburgh, Pittsburgh, PA,USA
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70.
Reply
EDITOR,—In 1996, Satsangi et al reported a
positive linkage between inflammatory bowel
disease (IBD) multiplex families (including
Crohn’s disease (CD), ulcerative colitis (UC)
and mixed families) with a locus (called
IBD2) located on chromosome 12.1 The
attributable risk in siblings (ës) of this IBD2
locus was calculated to be 2.1 In a recently
published study in the journal, we failed to
demonstrate a positive linkage on chromo-
some 12 using an independent panel of 95
CD multiplex families (Gut 2000;47:787–
91). This result was diVerent to the previous
report and we proposed several explanations
for the observed discrepancy.
The first explanation may be lack of statis-
tical power in our replication study. We inves-
tigated a similar number of aVected relative
pairs (n=157, all CD pairs) compared with
the first linkage analysis (n=186, 81 CD
pairs, 64 UC pairs, and 41 mixed pairs).
Because linkage tests may exhibit large
fluctuations when applied to family sets of
similar size for complex genetic disorders,2 we
tested if a gene with a ës risk of 2 was
compatible with our observation and we were
able to reject this hypothesis. We thus
concluded that genetic heterogeneity may
occur in Caucasian family panels for IBD
susceptibility.
Parkes et al have recently demonstrated
that this genetic heterogeneity may be related
to phenotypic heterogeneity.3 In their pro-
posed susceptibility model, UC is more
tightly linked to IBD2 than CD. This study
confirms our conclusion that there is genetic
heterogeneity in familial IBD. As expected,
this heterogeneity may be in part reduced by
an accurate phenotypic classification. Thus
from a methodological point of view, Parkes’
report demonstrates that working on homo-
geneous phenotypic groups may be prefer-
able than pooling several phenotypes for link-
age studies. Considering CD and UC families
as separate subgroups, Parkes et al suggested
that the IBD2 locus has only a marginal role
in CD susceptibility. This conclusion is in
complete accordance with our demonstration
that the relative risk attributable to IBD2 in
CD multiplex families is low.
In practice, it is diYcult to know what is the
weight of this IBD2 locus in both CD and
UC. A line of evidence, including the above
mentioned reports,3 and a large collaborative
work performed on more that 600 multiplex
IBD families4 clearly suggests that the role of
the IBD2 locus is weak in CD families. In
contrast, its role in UC is diYcult to estimate
to date. In their recent work, Parkes et al
pooled previously investigated families from
UK and US panels.1 5 Because these families
were a priori known to be positively linked to
IBD2, this study provides a biased estimate of
the risk attributable to IBD2. Thus additional
works using unselected family panels are
required to answer this question.
Interestingly, the IBD1 locus6 has been
postulated to play a major role in CD and to
be less important in UC families. Thus it
would be postulated that IBD1 is a CD
susceptibility locus and IBD2 is a UC gene.
Some truth may reside in this assertion.
However, a line of evidence including analysis
of mixed families7 suggests that CD and UC
have common familial risk factors and does
not allow a simple dichotomic classification
of UC and CD genes. Many additional steps,
including gene identification, are now re-
quired before we can understand the under-
lying genetic model for IBD which will
certainly be confirmed as a complex genetic
disorder.
S LESAGE
H ZOUALI
J P HUGOT
Fondation Jean Dausset CEPH,
27, rue Juliette Dodu, 75010 Paris, France
Correspondence to: J P Hugot. hugot@cephb.fr
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Intestinal permeability: the
cellobiose/mannitol test
EDITOR,—I should like to bring to your
attention a conceptual error in the paper by
Daniele et al (Gut 2001;48:28–33) regarding
the cellobiose/mannitol test. The authors sug-
gest that improvement in the cellobiose/
mannitol ratio reflects improvement in perme-
ability from the use of oral glutamine.
However, only mannitol excretion improved
significantly with glutamine; cellobiose excre-
tion remained unchanged. As the authors
explain in their methods section, it is the
increased cellobiose excretion that reflects
increased permeability, not the decrement in
mannitol excretion. Therefore, modifications
in sugar transport induced by 5-fluorouracil
(5-FU) reflected only an absorptive, not a per-
meability, defect. The decrement in mannitol
excretion parallels the decrement in D-xylose
excretion, probably reflecting decreased trans-
cellular passage of the test sugars induced by
5-FU and improved with glutamine.
R M CRAIG
Department of Gastroenterology and Hepatology,
Northwestern University, Chicago, Illinois 60611, USA
r-craig@northwestern.edu
Reply
EDITOR,—I thank Dr Craig for raising this
issue but I do not see any conceptual error.
The apparent inconsistency that he points
out in our paper (Gut 2001;48:28–33) is due
to the controversy surrounding transcellular
permeation of mannitol, as well as of other
monosaccharides.1 While transcellular per-
meation of mannitol is well known, its use for
osmotic shrinkage of membrane vescicles2
and as an extracellular fluid volume marker
suggests that, at least in part, mannitol
diVuses through the intercellular tight junc-
tions. Thus it seems justified talking of
permeability for mannitol. One of the reasons
for its use in combination with cellobiose is
the diVerent molecular sizes of the two
probes: the smaller size of mannitol allows its
passage through the small tight junctions of
the villi while the larger cellobiose passes
through the larger tight junctions of the
crypts.
Finally, we did find an increase in cello-
biose excretion after fluorouracil (5-FU) that
was in part prevented by oral glutamine.
Although this diVerence did not reach statis-
tical significance, overall the data indicate
increased intestinal permeability after 5-FU,
partially prevented by oral glutamine.
B DANIELE
Divisione Di Oncologia Medica B,
Istituto Nazionale Tumori, via M Semmola,
80131 Napoli, Italy
bdaniele@sirio-oncology.it
1 Bjarnason I, Macpherson AJ, Hollander D.
Intestinal permeability: an overview. Gastroen-
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2 Kessler M, Acuto O, Storelli C, et al.A modified
procedure for the rapid preparation of eY-
ciently transporting vescicles from small intes-
tinal brush border membranes.Biochim Biophys
Acta 1978;506:136–54.
Evaluation of the role of CFTR in
alcohol related pancreatic disease
EDITOR,—In up to 30% of patients with idio-
pathic pancreatitis (IP) a mutation of at least
one or both alleles of the cystic fibrosis trans-
membrane conductance regulator (CFTR)
gene can be identified.1–3 The study by Malats
et al (Gut 2001;48:70–4) addressed the ques-
tion of whether CFTR mutations, possibly
together with environmental factors such as
alcohol, may be associated with chronic pan-
creatitis or pancreatic cancer. The vast
majority of the pancreatic patients (86.4%)
investigated by Malats et al were diagnosed as
having alcoholic pancreatitis (AP), and
75.4% of the cancer patients were daily
drinkers. The authors found no statistically
significant diVerence in the prevalence of
delta-F508 (0%; 2.4%) and the 5T allele
(10.5%; 5.5%) in the AP or cancer groups
compared with the expected prevalence in the
general population. The lack of a positive
association of both delta-F508 and the 5T
allele with AP is neither surprising nor argues
against involvement of CFTR variations in
the development of AP, considering the
following.
In cystic fibrosis (CF), the degree of corre-
lation between CFTR genotype and CF phen-
otype varies between clinical components but
is highest for pancreatic involvement.4 CFTR
mutations can simplify be divided into
“severe” and “mild” with respect to the
degree to which mutations impair CFTR
function.5 Approximately 85% of CF patients
suVer from pancreatic insuYciency (PI)
while ∼15% are pancreatic suYcient (PS).
Generally patients with PI carry two “severe”
mutations whereas PS is associated with at
least one “mild” mutation (fig 1). In CF, pan-
creatitis is seen rather frequently in PS
patients but not in PI patients. Today, more
than 850 CF mutations have been reported to
the CF Consortium (http\www.genet.
sickkids.on.ca/cftr). The deletion delta-F508,
accounting for about 70% of mutant CF alle-
les worldwide and approximately 53% in
Spain, studied by Malats et al, is responsible
for severe functional loss of CFTR function.
Three additional studies on the prevalence of
an abnormal CFTR allele in AP have been
published as full papers.3 6 7 Pooling these
four studies, one or two mutant CFTR alleles
were detected in 9/217 (4.1%) patients with
AP. But the detection rate varies between 0%
and 8.5% depending on the sensitivity of the
screening method to detect an abnormal CF
allele in the corresponding population (53–
94%). None of the studies revealed a positive
association of the 5T allele with IP or AP.
Compared with the general population,
delta-F508 was significantly more frequent in
British and US Caucasian, but not in
Australian or Spanish AP patients.
Up to now no environmental or genetic
cofactor was identified in patients with
mutant CFTR alleles associated IP, suggest-
ing that impairment of CFTR function alone
may be enough to induce pancreatitis.1 2 3 8 9
On the other hand it may be speculated that
patients with an abnormal CFTR allele, who
develop pancreatitis in conjunction with
alcohol abuse, may be characterised by a
higher residual CFTR function, which by
itself is not capable of inducing pancreatitis.
Therefore, to delineate the genetic back-
ground of pancreatic disease in AP it seems to
be more appropriate to investigate the preva-
lence of uncommon mild variants (“atypical
mutations”) in large cohorts of AP patients
than to test for the more common (“severe,
typical”) mutations of the CFTR gene in
small patient groups. It has to be considered
that the test kits for CFTR mutations often
used in routine screening are usually de-
signed to detect the more severe CF muta-
tions. This would result in missing a substan-
tial number of patients with milder CFTR
mutations, as suggested by preliminary data
on more comprehensive genetic testing in
patients with ICP.8
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Reply
EDITOR,—We agree with the view of Ockenga
et al that from an ideal research perspective a
complete analysis of the cystic fibrosis trans-
membrane conductance regulator (CFTR)
gene should be performed for cases of
pancreatitis before a definitive statement on
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Figure 1 Disease manifestation according to
residual cystic fibrosis transmembrane
conductance regulator (CFTR) function as a
result of the combination of severe or mild
CFTR genotype. CF, cystic fibrosis; PS,
pancreatic suYciency; PI, pancreatic
insuYciency; CBAVD, congenital absence of the
vas deferens.
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the role of this gene in chronic pancreatitis
can be made. However, it is well known that
18–30% of patients with CFTR related
disorders (congenital bilateral absence of the
vas deferens and bronchiectasis) have only
one CFTR mutated allele.1–3 Thus despite our
study being based on only the two most com-
mon CFTR mutations (F508del and 5T),
these two alterations should suYce to rule out
or confirm a potential role of CFTR in
patients with chronic pancreatic diseases.
Furthermore, complete analysis of CFTR in
the general population has led to the identifi-
cation of amino acid variants of yet unknown
functional significance in about 10% of
subjects.4 It is highly likely that complete
analysis of CFTR would render a large
number of amino acid changes of uncertain
clinical and functional consequences, as it has
been shown for patients with asthma.5 As we
proposed in our paper (Gut 2001;48:70–4),
only the design of large studies specifically
addressing these issues in target and adequate
control populations and a comprehensive
molecular analysis of CFTR will answer the
question on the role of this gene in chronic
pancreatic disease.
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Alcohol, obesity, and TNF-á
EDITOR,—The conclusions reached by Wigg
et al (Gut 2001;48:206–11) about the origin
and importance of tumour necrosis factor á
(TNF-á) in non-alcoholic steatohepatitis
(NASH) patients have failed to take into
account the relationship between even mod-
est alcohol consumption and TNF-á produc-
tion and function. The authors found a lack
of correlation between obesity and TNF-á
levels in NASH patients and concluded that
TNF-á, which they see as central to the
pathogenesis of the condition, must have
other sources.
We first described the strong correlation
between obesity and serum TNF-á in 1998.1
Adipose tissue synthesises a number of
proinflammatory cytokines.2 The negative
correlation found in the Adelaide study is
surprising given the findings in larger studies
of non-NASH subjects and may be due to the
small study numbers and not correcting for
modest alcohol intake.
Alcohol consumption is considered a risk
factor for the development and progression of
liver disease in patients with fatty livers. We
previously showed a strong negative correla-
tion between any alcohol consumption and
serum TNF-á levels in a general population
sample. Modest alcohol consumption is
known to suppress TNF-á production by
monocytes, probably by suppressing post-
transcriptional TNF-á production.3 Further-
more, alcohol also has eVects on TNF-á
function mediated via high density lipopro-
tein (HDL). Alcohol enhances HDL levels by
stimulating lipoprotein lipase activity in
adipose tissue.4 HDL not only inhibits
TNF-á release from macrophages5 but also
protects certain cells against TNF-á induced
damage.6
If TNF-á is important, then modest
alcohol intake should be protective via
suppression of TNF-á. This raises the possi-
bility that TNF-á is not important in early
steatohepatitis.
In defining patients with NASH, alcohol
consumption must be rigorously excluded. In
the Adelaide study, 10 of 22 patients drank
up to 20 g of alcohol per day; however, even
modest amounts of alcohol have eVects on
TNF-á levels and function.
The known interaction between alcohol
and obesity in the pathogenesis of fatty liver
and steatohepatitis suggests that investigators
must look to factors other than TNF-á in
studying the early pathogenesis of this condi-
tion. In the same way that altered cytokine
homeostasis has been implicated in alcoholic
liver disease, NASH is probably caused by
changes to more than one proinflammatory
cytokine. Interleukin 6 (IL-6) is a proinflam-
matory cytokine, a hepatocyte stimulating
factor, and inhibitor of hepatic apoptosis. It
has been suggested that hepatic steatosis is
due to the rate of hepatocyte apoptosis
becoming insuYcient to match the rate of
hepatocyte proliferation.7 IL-6 induced liver
regeneration may render the liver more
susceptible to the eVects of other insults.
Unlike TNF-á, serum IL-6 exhibits a positive
correlation with both obesity and alcohol
intake (fig 1).1 8 So far IL-6 has not been
studied in the aetiology of NASH.
Future studies examining the link between
TNF-á and NASH will need to rigorously
control for alcohol consumption and assess
many other aspects of the inflammatory cyto-
kine network.
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Reply
EDITOR,—Our recent paper found increased
small bowel bacterial overgrowth (50% ver-
sus 22%) and twofold increased systemic lev-
els of tumour necrosis factor á (TNF-á) in
patients with non-alcoholic steatohepatitis
(NASH) compared with control age and sex
matched subjects (Gut 2001;48:206–11).
Poullis and Mendall question the finding of
elevated TNF-á levels in blood in NASH
subjects and quote their own work of elevated
TNF-á levels in obese, male, middle aged
subjects.1 There was no correlation between
TNF-á levels and obesity in our study
whereas their study showed a correlation with
obesity. How can this be explained? The
question comes down to whether TNF-á is
being produced predominantly in adipose
tissue or in the liver, and which of these con-
tributes to elevated systemic levels. At the
moment this cannot be resolved. TNF-á will
need to be investigated in liver biopsies and
TNF-á levels sampled from the hepatic vein
(not entirely impossible). The same should
be done in animal models of obesity. In the
meantime, it would be important to ascertain
what proportion of obese patients have
unrecognised NASH and whether this could
explain the elevated TNF-á levels in obesity.
Several lines of evidence suggest TNF-á is
upregulated in the liver in alcoholic liver dis-
ease and presumably this is reflected by raised
serum levels. We doubt therefore whether a
low (<20 g/day) consumption of alcohol
reduces systemic TNF-á levels but this could
be formally studied. We have re-examined
our data and found that there is no diVerence
in mean TNF-á levels between those who
Figure 1 Relationship between the cytokines
tumour necrosis factor á (TNF-á) and
interleukin 6 (IL-6), and obesity and alcohol.
BMI, body mass index.
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reported no alcohol consumption and those
who drank alcohol. Finally, we would also
comment from our recent work that shows
that the C14-D-xylose/H2-CH4 breath test is
only positive in 60–69% of cases of small
bowel bacterial overgrowth,2 mostly because
it depends on bacterial overgrowth being
present on the day of testing. Thus small
bowel overgrowth may have contributed even
more to NASH than indicated in our paper.
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BOOK REVIEWS
Dyspepsia: The Clinical Consequences.
Edited by V Heatley, P Moncur (£69.50).
UK: Blackwell Science, 2000. ISBN
0-632-05458-1.
Dyspepsia is like pornography—everyone
thinks they know what it is but no one can
agree on a definition. This is where the anal-
ogy ends, however, as there are plenty of
books on pornography but few have been
written on dyspepsia compared with other
areas of gastroenterology. Out of idle curios-
ity I searched the Internet for books on irrita-
ble bowel syndrome and found 25 published
in the past five years compared with only
three titles specifically on dyspepsia. This is
surprising given that dyspepsia represents
50% of a gastroenterologist’s workload and it
is refreshing to see an up to date book on the
subject.
The book discusses the epidemiology,
pathophysiology, diagnosis, and treatment of
dyspepsia in a methodical fashion. There are
contributions from an illustrious list of
authors many of whom have international
reputations in the field of dyspepsia research.
Each chapter acts as a well informed review
on a particular aspect of dyspepsia. The edi-
tors and contributors are to be congratulated
on ensuring each piece is authoritative yet
relatively short and accessible. This approach
means that the reader can dip into a chapter
most relevant to them and receive up to date
information on that topic.
If you read the book from cover to cover
however the introductions to each chapter
become somewhat repetitive. I became a little
tired of hearing about the clinical importance
of dyspepsia. There is a chapter on the
definition of dyspepsia and yet five other
chapters also define the condition. This can
be confusing as some characterise dyspepsia
as any symptom referable to the upper
gastrointestinal tract whereas others take the
more restrictive Rome II definition. The edi-
tors have taken a very broad definition of
dyspepsia and have included chapters on
gastro-oesophageal reflux disease. This will
probably irritate some experts who believe
reflux disease should be excluded. However,
there is no diagnostic test for dyspepsia and
therefore attempts at defining it become
reminiscent of theological arguments about
how many angels will fit on the point of a
needle.
Another minor quibble is that there were
only two chapters explicitly discussing Helico-
bacter pylori and dyspepsia. I realise that H
pylori is only one of many causes of dyspepsia
but given that this is one of the major discov-
eries in medicine over the past 20 years, more
information on the organism might have been
appropriate.
A more major criticism is that the book
does not have a chapter that specifically
discusses the management of dyspepsia. This
is touched on in a few chapters but there are
no firm conclusions reached and recent
important trials in this area are not fully dis-
cussed. This book may therefore disappoint
clinicians wanting a more didactic text on the
evidence for the management of dyspepsia.
I would warmly recommend this book to
all gastroenterologists with an interest in dys-
pepsia. This is a rapidly changing field which
hopefully will be reflected in new editions of
this work.
P MOAYYEDI
Nausea and Vomiting. Overview,
Challenges, Practical Treatments and
New Perspectives. RH Blum, WL
Heinrichs, A Herxheimer (Pp 620; illustrated;
£79.50/$135). Philadelphia: Whurr
Publisher, 2000. ISBN 1-86156-079-6.
Nausea is an extraordinarily common and
under appreciated symptom that aZicts
patients and non-patients alike. In a North
American population, approximately 15% of
subjects surveyed had moderate to severe
nausea in the past month. Thankfully, the
nausea most of us experience is brief and self
limited. Almost all of the medical and surgical
subspecialties however have patients who are
intermittently and chronically nauseated.
Unfortunately, little progress has been made
in the study of nausea from a pathophysi-
ological and treatment viewpoint.
The authors of the book seek to change this
situation and have produced a most interest-
ing and readable book about nausea and
vomiting for students, primary care physi-
cians, and researchers interested in these
unique human symptoms. Gastroenterolo-
gists with a clinical or research interest in
nausea and vomiting will also find this book
helpful in that it brings together a large
amount of information that is not easily
accessible to us.
The book is basically divided into three
parts: in the first 14 chapters the relevant anat-
omy and physiology of nausea and vomiting,
various research methodologies, therapeutics,
relevant neuropeptides, and the economic
impact of nausea and vomiting are covered.
Next there are 18 chapters outlining “hands
on” advice for diagnosing and treating the
patient with nausea and vomiting. Finally, the
last chapter in an excellent and extensive essay
on nausea/vomiting as an evolutionary re-
sponse of the ancient reptilian brain: the
reptilian brain appears to be responding to an
increasing number of nauseogenic precipitants
created by our modern lifestyles, technologies,
and therapeutics, as well as specific diseases/
disorders. Why is this?
The authors raise many provocative issues.
They reject the simplistic notion that nausea
and vomiting are regularly activated as a
response to a putative ingestion of toxic
substances. This time honoured concept sim-
ply does not reflect the many situations where
nausea and vomiting occur in the absence of
toxic ingestants. Olfactory system stimuli are
discussed in detail with regards to nausea and
vomiting during pregnancy. The authors
review an interesting concept that relates nau-
sea and vomiting and gravity, as gravitational
forces aVect the basic organisation of brain
function. Refreshing ideas and perspectives on
nausea and vomiting are oVered that encom-
pass philosophy and psychology viewpoints, as
well as physiology and pharmacology.
Nausea is more debilitating than vomiting.
The authors argue that nausea should be
clearly separated from vomiting in terms of
studying pathophysiological mechanisms and
developing therapies. Indeed, vomiting is the
cure for nausea (at least temporarily)! Nausea
is an “early warning system” evoked as the
organism attempts to maintain homeostasis
in response to the nauseogenic stimuli.
Vomiting is described as an “accident” of
cascading stimuli that ultimately overwhelm
homeostasis and the inhibitory circuits that
prevent the uncontrollable and potentially
injurious vomiting reflex.
Gastroenterologists are not the only medi-
cal providers dealing with the problems of
nausea and vomiting. “Nausea is in the air;
nausea is everywhere” is a phase I often use
when lecturing about the multidisciplinary
problem of nausea and vomiting. The second
major portion of the book incorporates 18
chapters in which a practical approach to the
diagnosis and treatment of nausea and
vomiting is described for many medical and
surgical specialties. From allergy and immu-
nology to gastroenterology, oncology, sur-
gery, and sports and space medicine these
chapters are an introduction to the treatment
of nausea and vomiting by various specialists.
These chapters are a bit uneven in their
thoroughness and somewhat redundant in
that each specialty ultimately uses similar
drugs and comfort techniques for their
patients. The tremendous lack of progress in
the therapy for nausea and vomiting makes
this area an open field for drug and non-drug
development.
The final chapter is an extensive essay on
nausea and vomiting that encompasses
stimulating paragraphs that are well worth
reading for any student of nausea and vomit-
ing symptoms. Topics range from the adap-
tive purpose of nausea as a warning sign of
ongoing problems in the internal/external
environment, as marshalling social support
for the suVerer, and as a powerful stimulus for
problem solving to avoid these symptoms in
the future.
I highly recommend this book as thoughtful
and thought provoking reading for anyone
interested in the common and sometimes
debilitating symptoms of nausea and vomiting.
The authors provide excellent reviews and new
insights that are now necessary to consider in
the fight against nausea and vomiting.
K KOCH
314 Letters, Book reviews, Correction,Notices
www.gutjnl.com
 on 28 July 2008 gut.bmj.comDownloaded from 
Inflammatory Bowel Disease. D S
Rampton, F Shanahan (Pp 108; illustrated;
£12.00). Oxford UK: Health Press, 2000.
ISBN 1-899541-49-7.
Would I feel tempted to buy this book? At
£12.00 it is a give away price and an excellent
buy. It provides an up to date and easily read
guide to our present understanding of the
cause, diagnosis, and management of Crohn’s
disease and ulcerative colitis. It certainly pro-
vides an authoritative handbook for specialist
registrars or even concerned patients. Its one
weakness lies in the absence of references—
but within 100 pages could one realistically
expect to achieve this? Its role as a handbook
for a consultant is less clear. Most of the
information it contains should be already
known to him or her, but it certainly could
refresh that knowledge.
Inflammatory bowel disease is laid out in
an attractive format with clear subtitles,
useful summary tables, and a good range of
illustrations. The impact of inflammatory
bowel disease on aspects of life such as fertil-
ity, sexual relations, education, employment,
and the consequences of the disease in child-
hood are dealt with in a limited way. The
growing role of the specialist nurse in
counselling and support is not considered in
the book although it could provide useful
background reading for anyone working in
such a role.
I was particularly impressed by the inclu-
sion of such esoteric treatments as arsenic
suppositories in the text although this was
omitted from the index. Remicaide was also
absent from the index but dealt with in the
text. In future editions the index could be
strengthened by a more uniform inclusion of
key terms. Another useful innovation could
be the listing of reliable web sites.
With the growth of expensive, lengthy, but
definitive textbooks that are almost by defini-
tion out of date at the time of publication,
there is a clear need for cheap authoritative
works that will have a relatively short shelf life
and can be quickly revised or replaced. The
philosophy behind the Health Press gives
hope that they may be able to fill this impor-
tant niche in the medical book market. Criti-
cal to this approach is the need for low cost.
J F MAYBERRY
Practice of Therapeutic Endoscopy, 2nd
edn. Edited by G N J Tytgat, M Classen, J D
Waye, et al (Pp 328; illustrated; £99.95).
Philadelphia: WB Saunders Co, 2000. ISBN
0702025615.
We are in the throes of a revolution in the
printing world, the ramifications of which
cannot be accurately foreseen but are cer-
tainly as likely to have as dramatic eVect on
global culture as did Johann Gutenberg’s
invention of printing in the 15th century.
Maybe we should all be pleased that we are
living right in the middle of the revolution in
communications technology. It is an endless
source of fascination to listen to those who
just a few years ago could not distinguish a
RAM from a ROM, now feeling free to wax
lyrical to all within earshot about the latest bit
of “state of the art” technology that they own.
How good it is to be at the cutting edge of
information technology.
Yet, maybe not everyone is head over heels
in love with IT. While the medical and particu-
larly the academic community are keen to
grasp all the opportunities, there must be
many publishers who are rather fearful about
what the future might bring. For them, like for
almost all of us, change brings uncertainty. But
it is not good to question technological
progress in the UK just now. We have a mod-
ernising government and its leader is fond of
saying that he is proud of his country’s past,
but he does not want to live in it!
So what will modernisation bring to the
publishing world. A whole generation is now
being brought up to look upon the personal
computer as the main means of communica-
tion. Conventional correspondence is now
sneeringly dismissed as “snail mail”. Maybe
daily newspapers will hang in there a bit
longer but what is the future of medical jour-
nals?
All of these thoughts were going through
my mind as I read this book, the first edition
of which was published six years ago. The
sheer range of what can now be done
interventionally through an endoscope is
quite breathtaking. There is a series of essays
on therapeutic endoscopy nearly all of which
are of very high quality indeed. The pub-
lisher, WB Saunders, has served the editors
very well. I think this book has been most
beautifully produced—the illustrations are
generally very fine and the reproduction of
colour photographs is quite superb. This is a
book that should be read by every trainee.
Yet there is a problem. It is something of a
truism that medical textbooks are out of date
before they are published. Of course that is
always true, even in an area such as this where
the pace of technological progress out speeds
the publishing schedule. However, the prob-
lem here is rather deeper. In many ways, this
book is a manual. It is full of helpful tips on
“how to do it” and it is very good on pitfalls
and how to avoid them. The problem is that
the medium of a textbook just cannot be the
way of the future for this sort of book. As
most of the neologisms in the IT language,
multimedia is a fairly ghastly word,
nevertheless one just feels there ought to be a
CD or DVD to go with the book.
Whether anybody will be publishing books
like this in five years time is anyone’s guess—
but I wouldn’t bet on it. Doubtless trees will
be happier but in any case the present
publishers state proudly in a preface that their
policy is “to use paper manufactured from
sustainable forests”. Jolly good of them too!
I FORGACS
CORRECTIONS
An error occurred in the Science @lert article
by Playford RJ (Gut 2001;48:594–5). The
text and reference 1 should refer to the author
“Kinzler” and not “Kinzlker”. Professor
Playford apologises for the incorrect spelling.
The authors of Gut 2001;48:816–20 have
notified the journal of a computational error
they made in figure 2. The correct figure is
printed here. The one line of text that
describes the figure, under the heading “intra-
hepatic cholangiocarcinoma” on p817, should
now read, “There was, on average, a 12-fold
increase in ASpMR per 100 000 population in
ages 45 and above, with larger increases at
older ages and in women (fig 2A, B)”. The
authors apologise for this error, and wish to
point out that all the rest of the data are
correct, and this does not change the findings
reported upon in the paper or the interpret-
ation.
NOTES
Sir Francis Avery Jones British Society
of Gastroenterology Research Award
2002
Applications are invited by the Education
Committee of the British Society of Gastro-
enterology who will recommend to Council
the recipient of the 2002 Award. Applications
(TWENTY COPIES) should include:
+ A manuscript (2 A4 pages ONLY) de-
scribing the work conducted
+ A bibliography of relevant personal publi-
cations
+ An outline of the proposed content of the
lecture, including title
+ A written statement confirming that all or
a substantial part of the work has been
personally conducted in the UK or Eire.
Entrants must be 40 years or less on 31
December 2001 but need not be a member of
the Society. The recipient will be required to
deliver a 30 minute lecture at the Annual
meeting of the Society in Birmingham in
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Figure 2 Age specific mortality rates per
100 000 population in England and Wales in
(A) females and (B) males for intrahepatic
cholangiocarcinoma.
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March 2002. Applications (TWENTY COP-
IES) should be made to the Honorary Secre-
tary, British Society of Gastroenterology,
3 St Andrews Place, London NW1 4LB by
1 December 2001.
Hopkins Endscopy Prize 2002
Applications are invited by the Endoscopy
Committee of the British Society of Gastro-
enterology who will recommend to Council
the recipient of the 2002 Award. Applications
(TEN COPIES) should include:
+ A manuscript (2 A4 pages ONLY) de-
scribing the work conducted
+ A bibliography of relevant personal publi-
cations
+ An outline of the proposed content of the
lecture, including title
+ A written statement confirming that all or
a substantial part of the work has been
personally conducted in the UK or Eire.
An applicant need not be a member of the
Society. The recipient will be required to
deliver a 20 minute lecture at the Annual
meeting of the Society in Glasgow in March
2002. Applications (TEN COPIES) should be
made to the Honorary Secretary, British Soci-
ety of Gastroenterology, 3 St Andrews Place,
London NW1 4LB by 1 December 2001.
Falk Symposium No 123: VI
International Symposium on
Inflammatory Bowel Diseases
This Falk Symposium will be held on 3–5
September 2001 in Istanbul, Turkey. Further
information: Falk Foundation e.V. - Congress
Division, Leinenweberstr. 5, PO Box 6529,
D-79041 Freiburg, Germany. Tel: +49 761
15 14 0; fax: +49 761 15 14 359; email:
symposia@falkfoundation.de
Falk Symposium No 124: Medical
Imaging in Gastroenterology and
Hepatology
This Falk Symposium will be held on 28–29
September 2001 in Hannover, Germany.
Further information: see Falk Symposium
No 123 above.
9th Asian Conference on Diarrheal
Diseases and Nutrition
This meeting will be held on 28–30 Septem-
ber 2001 in New Delhi, India. The organisers
hope the meeting will promote meaningful
and eVective collaboration among
individuals/institutions towards control of the
major health problems in Asia, particularly
those aVecting women and children. Further
information: Professor M K Bhan, Coordina-
tor, Centre for Diarrheal Disease and Nutri-
tion Research, All India Institute of Medical
Sciences, New Delhi. Tel: +91 11 6963822;
fax: +91 11 6862662; email:
ascodd2001@rediVmail.com
VI Congress of the International
Xenotransplantation Association
This congress will be held on 29 September
to 3 October 2001 in Chicago, USA. Further
information: Felicissimo & Associates Inc.,
205 Viger Avenue West, Suite 201, Montreal,
Quebec, Canada H2Z 1G2. Tel: +1 514 874
1998; fax: +1 514 874 1580; email:
info@ixa2001chicago.com; website:
www.ixa2001chicago.com
Falk Symposium No 125: Cytokines in
Liver Injury and Repair
This Falk Symposium will be held on 30
September to 1 October 2001 in Hannover,
Germany. Further information: see Falk
Symposium No 123 above.
Falk Symposium No 126: Hepatocyte
Transplantation
This Falk Symposium will be held on 2–3
October 2001 in Hannover, Germany. Fur-
ther information: see Falk Symposium No
123 above.
EASL Single Topic Conference
The EASL Single Topic Conference “Liver
fibrosis: from basic science to clinical targets”
will be held on 12–13 October 2001 in Flor-
ence, Italy. Organisers: Massimo Pinzani
(University of Florence) and Detlef Schup-
pan (University of Erlangen-Nuernberg).
The aim of the conference is to provide the
latest information on this key area of hepatol-
ogy and to translate the current knowledge
into clinical terms. It is directed at both the
expert in the field and the general hepatolo-
gist. Further information: Massimo Pinzani,
Dipartimento di Medicina Interna, Univer-
sità degli Studi di Firenze, Viale GB Mor-
gagni, 85, I-50134 Firenze, Italy. Tel: +39
055 4277845; fax: +44 39 055 417123;
email: m.pinzani@dfc.unifi.it
Lecture Course in Coloproctology
This course will be held on 15–17 October
2001 in Harrow, UK. Professor Russell Stitz
from Australia will be the Sir Alan Parks Vis-
iting Professor and, for the first time, there
will be a Sir Francis Avery Jones Visiting Pro-
fessor, which will be Professor Paul Rutgeerts
from Belgium. Further information: The
Administrator, St Mark’s Academic Institute,
St Mark’s Hospital, Northwick Park, Harrow,
Middx, HA1 3UJ, UK. Tel: +44 (0)20 8235
4046/8; fax: +44 (0)20 8235 4039; email:
stmarks@ic.ac.uk; website: www.stmarkshos-
pital.org.uk
International Symposium on
Hyperammonemia, Liver Failure and
Hepatic Encephalopathy
This symposium will be held on 20–22 Octo-
ber 2001 in Valencia, Spain. Further infor-
mation: Cátedra Santiago Grisolía, Fun-
dación Museu de les Ciències Príncipe
Felipe, Ciutat de les Arts i les Ciències, Avda.
Instituto Obrero, s/n, 46013 Valencia, Spain.
Tel: +34 96 197 44 66; fax: +34 96 197 44 70;
email: catedrasg@cac.es.
ICGH-2: The Second Iranian Congress
of Gastroenterology and Hepatology
The main Iranian meeting of gastroenterolo-
gists and researchers in this field will be held
on 27 October to 1 November 2001 in
Tehran, Iran. Further information: Dr Shahin
Merat, Digestive Diseases Research Center,
Shariati Hospital, N. Kargar Street, Tehran
14114, Iran. Tel: +98 911 717 3966; fax: +98
21 225 3635; email: merat@ams.ac.ir; web-
site: www.ams.ac.ir/icgh.
Falk Symposium No 127: Autoimmune
Diseases in Pediatric Gastroenterology
This Falk Symposium will be held on 8–9
November 2001 in Basel, Switzerland. Fur-
ther information: see Falk Symposium No
123 above.
42nd Annual Conference of the Indian
Society of Gastroenterology
This conference will be held on 23–29
November 2001 in Lucknow, India. The pro-
gramme includes two pre-conference sympo-
sia (on gastrointestinal motility and scientific
communication, on 23 November), a one day
postgraduate course or CME (24 Novem-
ber), and an endoscopy workshop (28–29
November). Further information: Dr S R
Naik, Department of Gastroenterology,
SGPGI, Lucknow 226014, India. Tel: +91
522 440700 or 440800, ext 2400; fax: +91
522 440078 or 440017; website:
www.sgpgi.ac.in/conf/isg2001.html
41st St Andrew’s Day Festival
Symposium on Therapeutics
This will be held on 6–7 December 2001 in
Edinburgh, UK. Further information: Ms
Eileen Strawn, Syposium Co-ordinator. Tel:
+44 (0)131 225 7324; fax: +44 (0)131 220
4393; email: e.strawn@rcpe.ac.uk; website:
www.rcpe.ac.uk
14th Intensive European Course of
Digestive Endoscopy
This course will be held on 17–18 December
2001 in Strasbourg, France. Further infor-
mation: Michele Centonze Conseil, 6 bis rue
des Cendriers, 75020 Paris, France. Tel: +33
1 44 62 68 80; fax: +33 1 43 49 68 58; email:
mail@m-centonze-conseil.com
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